Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
Year: 2016
Type: article
Source: The Lancet Oncology
Institutions: The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, Aix-Marseille Université, Hôpital de la Timone, Mount Vernon Hospital, Mount Vernon Cancer Centre, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Université Paris-Sud, Institut Gustave Roussy, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, Novartis (Switzerland), Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funders: Bristol-Myers Squibb, Novartis
OpenAlex ID: W2551317550